MX2021016089A - Composición novedosa de ibuprofeno y acetaminofeno. - Google Patents

Composición novedosa de ibuprofeno y acetaminofeno.

Info

Publication number
MX2021016089A
MX2021016089A MX2021016089A MX2021016089A MX2021016089A MX 2021016089 A MX2021016089 A MX 2021016089A MX 2021016089 A MX2021016089 A MX 2021016089A MX 2021016089 A MX2021016089 A MX 2021016089A MX 2021016089 A MX2021016089 A MX 2021016089A
Authority
MX
Mexico
Prior art keywords
methods
scale
manufacture
ibuprofen
treatment
Prior art date
Application number
MX2021016089A
Other languages
English (en)
Spanish (es)
Inventor
Christine Drumheller Andrews
David Ellis Kellstein
Kevin Scott Kinter
Bonny Rene Shaw
Original Assignee
Glaxosmithkline Consumer Healthcare Holdings Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73543315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021016089(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Consumer Healthcare Holdings Us Llc filed Critical Glaxosmithkline Consumer Healthcare Holdings Us Llc
Publication of MX2021016089A publication Critical patent/MX2021016089A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2021016089A 2019-06-27 2020-06-24 Composición novedosa de ibuprofeno y acetaminofeno. MX2021016089A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962867683P 2019-06-27 2019-06-27
PCT/US2020/039321 WO2020263947A1 (en) 2019-06-27 2020-06-24 Novel ibuprofen and acetaminophen composition

Publications (1)

Publication Number Publication Date
MX2021016089A true MX2021016089A (es) 2022-04-25

Family

ID=73543315

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021016089A MX2021016089A (es) 2019-06-27 2020-06-24 Composición novedosa de ibuprofeno y acetaminofeno.

Country Status (13)

Country Link
US (3) US11918693B2 (enExample)
EP (1) EP3989944A1 (enExample)
JP (2) JP7703220B2 (enExample)
KR (1) KR20220027194A (enExample)
CN (1) CN114173767A (enExample)
AU (2) AU2020301401B2 (enExample)
BR (1) BR112021026407A8 (enExample)
CA (1) CA3143724A1 (enExample)
CO (1) CO2021017722A2 (enExample)
IL (1) IL288989A (enExample)
MX (1) MX2021016089A (enExample)
PH (1) PH12021553169A1 (enExample)
WO (1) WO2020263947A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7750663B2 (ja) * 2021-03-19 2025-10-07 エスエス製薬株式会社 被覆固形医薬製剤
WO2025212048A1 (en) * 2024-03-30 2025-10-09 Humanis Sağlik A.Ş. Pharmaceutical compositions comprising ibuprofen and paracetamol and relevant excipients
WO2025212049A1 (en) * 2024-03-30 2025-10-09 Humanis Sağlik A.Ş. Solid pharmaceutical compositions comprising ibuprofen and paracetamol

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL104904B1 (pl) 1977-02-11 1979-09-29 Zaklady Radiowe Radmor Sposob wytwarzania anteny z izolacyjna oslona z tworzyw sztucznych
US4757090A (en) 1986-07-14 1988-07-12 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
PL195966B1 (pl) 2001-02-23 2007-11-30 Zaklady Farmaceutyczne Polfa L Preparat farmaceutyczny przeciwbólowy
BRPI0512756A (pt) * 2004-07-07 2008-04-08 Aft Pharmaceuticals Ltd composição farmacêutica de combinação para o tratamento de dor, método de controle de dor, uso de uma composição e embalagem farmacêutica incluindo comprimidos ou cápsulas
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
GB0519350D0 (en) * 2005-09-22 2005-11-02 Boots Healthcare Int Ltd Therapeutic agents
CN101584673A (zh) * 2009-07-13 2009-11-25 浙江京新药业股份有限公司 一种左乙拉西坦片剂及其制备方法
CN102266301A (zh) * 2011-07-27 2011-12-07 蚌埠丰原涂山制药有限公司 一种非甾体抗炎药片及其制备方法
AU2016210691A1 (en) * 2015-08-05 2017-02-23 Beximco Pharmaceuticals Controlled release formulations of paracetamol
EP4480495A3 (en) * 2017-07-10 2025-06-18 Gel Cap Technologies, LLC Dual release dosage form capsule and methods, devices and systems for making same
WO2019108147A1 (en) 2017-11-29 2019-06-06 İlko İlaç Sanayi̇ Ve Ti̇caret A.Ş. Color stable fixed dose tablet combination of ibuprofen and paracetamol
US20190350883A1 (en) 2018-05-20 2019-11-21 Luan Chau Pharmaceutical Composition of Acetaminophen/Ibuprofen
US11197830B2 (en) * 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen

Also Published As

Publication number Publication date
JP2025134843A (ja) 2025-09-17
AU2020301401A1 (en) 2022-01-27
US20200405645A1 (en) 2020-12-31
KR20220027194A (ko) 2022-03-07
CN114173767A (zh) 2022-03-11
US11918693B2 (en) 2024-03-05
IL288989A (en) 2022-02-01
BR112021026407A2 (pt) 2022-02-08
BR112021026407A8 (pt) 2022-11-22
JP2022540348A (ja) 2022-09-15
US20250302754A1 (en) 2025-10-02
WO2020263947A1 (en) 2020-12-30
PH12021553169A1 (en) 2022-08-15
US20240156740A1 (en) 2024-05-16
EP3989944A1 (en) 2022-05-04
CA3143724A1 (en) 2020-12-30
CO2021017722A2 (es) 2022-01-17
JP7703220B2 (ja) 2025-07-07
AU2020301401B2 (en) 2023-12-21
AU2024200875A1 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
JOP20220020A1 (ar) مثبطات kars تعتمد على akr1c3 ثلاثية الحلقة
CA2990277C (en) Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
MX2018010427A (es) Formas solidas de un inhibidor de tienopirimidindiona acetil coa carboxilasa y metodos para su produccion.
MX2022016422A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
PH12019502782A1 (en) Fixed dose formulations
BR112014012878A8 (pt) composto, uso de um composto, composição farmacêutica e processos de fabricação de um composto
PH12020550132A1 (en) Novel enantiomers of a series of antiviral compounds
MX380122B (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
PH12021553169A1 (en) Novel ibuprofen and acetaminophen composition
MX2019007575A (es) Producción de novedosas preparaciones de beta-lactoglobulina y métodos, usos y productos alimenticios relacionados.
MX389515B (es) Proceso mejorado para producir fucoxantina y/o polisacáridos de microalgas.
CY1117123T1 (el) Παραγωγα οιστρα-1,3,5(10),16-τετραενο-3- καρβοξαμιδιου, μεθοδοι για την παραγωγη αυτων, φαρμακευτικα παρασκευασματα που τα περιεχουν καθως και η χρηση αυτων για την παραγωγη φαρμακευτικων μεσων
PH12019502093A1 (en) Novel ester compounds, method for the production thereof and use thereof
PH12015500106B1 (en) Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
EP4471130A3 (en) New immunoregulatory cells and methods for their production
ZA202107777B (en) Voruciclib polymorphs and methods of making and using thereof
MX2021015587A (es) Proceso para fabricar un producto analogo de carne formado.
SA522431585B1 (ar) تركيبات تروفينتايد
MY166555A (en) Substituted piperidine
MX2021015585A (es) Producto analogo de carne formado.
MX2020012065A (es) Compuestos de ciclopentano.
MX2020006641A (es) Proceso para la preparacion de compuestos de pirimidinil-4-aminopi razol.
BR112014019356A8 (pt) Método para produzir um ou mais produtos finais de fermentação e produto final de fermentação
TR201717703A2 (tr) Api̇ksaban formülasyonlari
ZA202100955B (en) Thrombin inhibitors, formulations, and uses thereof